Activation of Dendritic Cells by Soypeptide Lunasin: Implication in Vaccine Adjuvant

dc.contributor.authorFlores, Sarah
dc.contributor.authorDong, Melissa
dc.contributor.authorTung, Chun-Yu
dc.contributor.authorChang, Hua-Chen
dc.date.accessioned2014-10-09T17:31:03Z
dc.date.available2014-10-09T17:31:03Z
dc.date.issued2014-04-11
dc.descriptionposter abstracten_US
dc.description.abstractAdjuvants enhance the immunogenicity of vaccines and improve the immune responses. Although many adjuvants are currently used in research, FDA approved aluminum salt (Alum) remains the most often used in human vaccines. Alum is known to promote the Th2 immune response and enhance antibody production, but is less efficient on eliciting Th1 and CTL cellular responses. Thus, it is prudent to improve the effectiveness of current adjuvants or to develop a novel alternative adjuvant. We have recently identified lunasin, a seed peptide from soybeans, as a novel immune modulator. The objective is to define the effectiveness of lunasin peptide as an adjuvant that can enhance the protective immunity of vaccines. Our studies have revealed stimulatory effects of lunasin on dendritic cells (DCs) by regulating expression of a number of genes that are important for immune responses. Lunasin-treated human conventional DCs (cDCs) not only expressed elevated levels of co-stimulatory molecules (CD86) but also exhibited up-regulation of chemokines (CCL2, CCL3, CCL4) and cytokine (IL-1β). To determine the function of lunasin-treated cDCs, these cells were co-cultured with allogeneic human peripheral blood CD4+ T cells for 7 days in the mixed lymphocyte reaction. Lunasin-treated cDCs induced almost 2-fold higher proliferation of allogeneic CD4+ T cells when comparing with a sham treatment. To verify the in vivo effects, lunasin was administered into mice. Increased CD86 expression was found in cDCs from spleens of mice treated with lunasin. Furthermore, mice vaccinated with lunasin-adjuvanted ovalbumin (OVA) had reduced tumor growth following challenging with OVA-expressing A20 B-lymphoma cells. Taken together, our data suggest that lunasin may act as a vaccine adjuvant by targeting DCs to enhance and modulate the immune responses to antigens.en_US
dc.identifier.citationFlores, S., Dong, M., Tung, C., Chang, H. (2014, April 11). Activation of Dendritic Cells by Soypeptide Lunasin: Implication in Vaccine Adjuvant. Poster session presented at IUPUI Research Day 2014, Indianapolis, Indiana.en_US
dc.identifier.urihttps://hdl.handle.net/1805/5247
dc.language.isoen_USen_US
dc.publisherOffice of the Vice Chancellor for Researchen_US
dc.subjectadjuvantsen_US
dc.subjectvaccinesen_US
dc.subjectLunasinen_US
dc.titleActivation of Dendritic Cells by Soypeptide Lunasin: Implication in Vaccine Adjuvanten_US
dc.typeOtheren_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Flores-Activation.pdf
Size:
45.66 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: